Search results for "Gastroenterologia"

showing 10 items of 310 documents

PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C

2015

Summary Background The PNPLA3/Adiponutrin rs738409 C/G single nucleotide polymorphism is associated with the severity of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease, as well as the severity of steatosis and fibrosis in patients with chronic hepatitis C (CHC). Aim To test in genotype 1(G1)-CHC patients, the putative association between the PNPLA3 variant and histological features of steatohepatitis, as well as their impact on the severity of fibrosis. Methods Four hundred and thirty-four consecutively biopsied Caucasian G1-CHC patients were genotyped for PNPLA3 rs738409, its effect evaluated by using an additive model. Histological features of s…

Liver CirrhosisMaleHepacivirusGastroenterologyCohort StudiesNon-alcoholic Fatty Liver DiseaseFibrosisGenotypePharmacology (medical)ChronicMembrane ProteinSettore MED/12 - Gastroenterologiaeducation.field_of_studyMedicine (all)Fatty liverGastroenterologySingle NucleotideHepatitis CMiddle AgedHepatitis CFemaleHumanAdultmedicine.medical_specialtyLogistic ModelGenotypeLiver CirrhosiEuropean Continental Ancestry GroupSingle-nucleotide polymorphismSettore MED/08 - Anatomia PatologicaPolymorphism Single NucleotideWhite PeopleInternal medicinemedicineHumansAdiponutrinObesityPolymorphismeducationAdult; Cohort Studies; European Continental Ancestry Group; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Lipase; Liver Cirrhosis; Logistic Models; Male; Membrane Proteins; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Polymorphism Single Nucleotide; Pharmacology (medical); Medicine (all)HepaciviruHepatologybusiness.industryMembrane ProteinsLipaseHepatitis C Chronicmedicine.diseaseFatty LiverLogistic ModelsCohort StudieSteatosisSteatohepatitisbusinessAlimentary Pharmacology & Therapeutics
researchProduct

Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

2017

Background & Aims Assessment of long-term outcome is required in hepatitis C virus (HCV)-infected patients with cirrhosis, who have been successfully treated for Barcelona Clinic Liver Cancer (BCLC) stage A hepatocellular carcinoma (HCC). However, problems arise due to the lack of models accounting for early changes during follow-up. The aim of this study was to estimate the impact of early events (HCC recurrence or hepatic decompensation within 12Â months of complete radiological response) on 5-year overall survival (OS) in a large cohort of patients with HCV and cirrhosis, successfully treated HCC. Methods A total of 328 consecutive Caucasian patients with HCV-related cirrhosis and BC…

Liver CirrhosisMaleHepatocellular Carcinoma Liver Cirrhosis hepatitis C virus Survival direct-acting antiviral agentsSurvival rateCirrhosisAntiviral agentGastroenterologyLiver cirrhosi0302 clinical medicineRecurrenceHepatic decompensation; Hepatitis C Virus (HCV); Hepatocellular carcinoma (HCC); Prognosis; Recurrences; Sustained virological response (SVR); overall survival (OS)Overall survivalLiver NeoplasmsHepatitis Coverall survival (OS)Middle AgedPrognosisHepatitis CSustained virological responseLocal030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleAntiviral agents; Carcinoma hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response; Aged; Carcinoma Hepatocellular; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards ModelsLiver cancerHepatic decompensationmedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIA03 medical and health scienceshepatocellularInternal medicinemedicineEarly Hepatocellular CarcinomaHumansRecurrencesHepatocellular carcinoma (HCC)Survival rateAntiviral agents; Carcinoma hepatocellular; Hepatic decompensation; Hepatitis C; Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Recurrences; Survival rate; Sustained virological response; HepatologyAgedProportional Hazards ModelsHepatologybusiness.industryHepatitis C Virus (HCV)CarcinomaHepatocellularHepatologymedicine.diseasedigestive system diseasesNeoplasm RecurrenceAntiviral agentsLiver cirrhosisLiver functionNeoplasm Recurrence LocalbusinessSustained virological response (SVR)
researchProduct

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

2015

Aim: To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA).Patients and methods: A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13 %) with subtype 1a and 1,074 (87 %) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype.Results: At multivariate analysis, baseline characteristics differentiating patients …

Liver CirrhosisMaleMultivariate analysisclinical featuresChronic HCV liver diseaseType 2 diabetesSex FactorHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolstherapeutic outcomechemistry.chemical_compoundGenotypeAge FactorSettore MED/12 - GastroenterologiaSustained virologic responseAge Factorsvirus diseasesHCV genotype 1 subtypes (1a and 1b)Hepatitis CRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInterferonRNA ViralFemaleHCV subtypeHumanAdultmedicine.medical_specialtyGenotypeLiver CirrhosiAlpha interferonmacromolecular substancesInterferon alpha-2Antiviral AgentsSex FactorsDiabetes mellitusInternal medicineRibavirinmedicineHumansPeg-interferon and ribavirinAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterleukinstechnology industry and agricultureInterferon-alphaHepatologyInterleukinHepatitis C Chronicmedicine.diseaseVirologydigestive system diseaseschemistryDiabetes Mellitus Type 2HCV genotypeHCV genotype 1 subtypes (1a and 1b); clinical features; therapeutic outcomeInterferonshepatitis Cbusiness
researchProduct

The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease

2016

Abstract We tested whether nonalcoholic fatty liver disease (NAFLD) and/or its histological severity are associated with vascular white matter lesions (WML) in patients with biopsy-proven NAFLD and in non-NAFLD controls. Data were recorded in 79 consecutive biopsy-proven NAFLD, and in 82 controls with normal ALT and no history of chronic liver diseases, without ultrasonographic evidence of steatosis and liver stiffness value  45 years (OR 3.09, 95% CI: 1.06–9.06, P = 0.03; and OR 11.1, 95% CI: 1.14–108.7, P = 0.03), and F2–F4 fibrosis (OR 3.36, 95% CI: 1.29–8.73, P = 0.01; and OR 5.34, 95% CI: 1.40–20.3, P = 0.01) were independently associated with WML (mostly of mild grade) by multivariate…

Liver CirrhosisMalePathologyBiopsySeverity of Illness IndexGastroenterology0302 clinical medicineRisk FactorsNon-alcoholic Fatty Liver DiseaseFibrosisNonalcoholic fatty liver diseaseUltrasonography4500Brain DiseasesSettore MED/12 - Gastroenterologiamedicine.diagnostic_testMedicine (all)Brain DiseaseGeneral MedicineMiddle AgedMagnetic Resonance ImagingWhite MatterFrontal Lobemedicine.anatomical_structureLiverFemale030211 gastroenterology & hepatologyNAFLD liver biopsy fibrosis white matter lesionsResearch ArticleHumanmedicine.medical_specialtyLiver CirrhosiObservational StudySettore MED/08 - Anatomia PatologicaDiagnosis DifferentialWhite matter03 medical and health sciencesInternal medicineBiopsySeverity of illnessmedicineHumansbusiness.industryRisk Factornutritional and metabolic diseasesmedicine.diseasedigestive system diseasesHyperintensityDifferential diagnosisSteatosisSettore MED/36 - Diagnostica Per Immagini E Radioterapiabusiness030217 neurology & neurosurgeryMedicine
researchProduct

Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases.

2012

Background and Aims: Serum levels of γ-glutamyl-transpeptidase(γ-GT) were associated with liver disease severity and metabolic alterations, which in turn are able to affect hepatic damage. In patients with nonalcoholic fatty liver disease (NAFLD), genotype 1 chronic hepatitis C (G1CHC) and chronic hepatitis B (CHB), we assessed the link between liver fibrosis and γ-GT serum levels, and we evaluated if normal or high γ-GT serum levels affect the association between insulin resistance (IR) and severity of liver fibrosis. Methods: 843 consecutive patients with chronic liver disease (CLD)(193 NAFLD, 481 G1CHC, 169 CHB) were evaluated by liver biopsy (Kleiner and Scheuer scores) and clinical and…

Liver CirrhosisMalePathologylcsh:MedicineNonalcoholic SteatohepatitisChronic liver diseaseBiochemistryGastroenterologyCohort StudiesLiver diseaseEndocrinologyRisk FactorsFibrosisNonalcoholic fatty liver diseaseInsulinGamma-glutamyltransferaselcsh:ScienceSettore MED/12 - GastroenterologiaMultidisciplinarymedicine.diagnostic_testbiologyEnzyme ClassesLiver DiseasesFatty livergamma glutamyl transferase liver fibrosis insulin resistancegamma-GlutamyltransferaseMiddle AgedEnzymesLiver biopsyMedicineFemaleResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignGastroenterology and HepatologySettore MED/08 - Anatomia PatologicaTransferasesInternal medicinemedicineHumansStatistical MethodsBiologyDemographyEndocrine PhysiologyInfectious Hepatitisbusiness.industrylcsh:Rmedicine.diseaseChronic DiseaseMultivariate Analysisbiology.proteinlcsh:QInsulin ResistanceLiver function testsbusinessPLoS ONE
researchProduct

Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity

2019

Background & Aims: In patients with non-alcoholic fatty liver disease (NAFLD), liver biopsy is the gold standard to detect non-alcoholic steatohepatitis (NASH) and stage liver fibrosis. We aimed to identify differentially expressed mRNAs and non-coding RNAs in serum samples of biopsy-diagnosed mild and severe NAFLD patients with respect to controls and to each other. Methods: We first performed a whole transcriptome analysis through microarray (n = 12: four Control: CTRL; four mild NAFLD: NAS ≤ 4 F0; four severe NAFLD NAS ≥ 5 F3), followed by validation of selected transcripts through real-time PCRs in an independent internal cohort of 88 subjects (63 NAFLD, 25 CTRL) and in an external …

Liver CirrhosisMaleRNA UntranslatedMicroarrayBiopsyGastroenterologyliquid-biopsySeverity of Illness IndexTranscriptomeCohort Studies0302 clinical medicineFibrosisSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseMedicineSettore MED/12 - Gastroenterologiamedicine.diagnostic_testFatty liverArea under the curveNASHUntranslatedMiddle AgedLiver030220 oncology & carcinogenesisLiver biopsyDisease Progression030211 gastroenterology & hepatologyFemalefibrosiAdultmedicine.medical_specialty03 medical and health sciencesPredictive Value of TestsInternal medicineNAFLDliquid‐biopsyExtracellularHumansHepatologybusiness.industryGene Expression Profilingfibrosismedicine.diseaseRNAsMetabolic Liver DiseaseROC CurveRNASteatohepatitisbusinessBiomarkers
researchProduct

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cir…

2013

Genetic factors can influence the outcome of antiviral therapy in chronic hepatitis C (HCV). We evaluated the role of interleukin-28B single nucleotide polymorphisms (SNPs) and inosine triphosphatase (ITPA) gene variants in HCV cirrhosis treated with Peg-Interferon and ribavirin. A prospective cohort of 233 patients with compensated cirrhosis received 1-1.5 μg/kg/week of Peg-Interferon alpha-2b plus 1000-1200 mg/day of RBV for 48 weeks. A sustained virologic response (SVR) was achieved in 27% of patients. On multivariate logistic analysis, the absence of oesophageal varices (OR 3.64 CI 95% 1.27-10.44 P = 0.016), infection with genotype 2 or 3 (OR 4.06, CI 95% 1.08-15.26, P = 0.038), C/C all…

Liver CirrhosisMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaAnemia HemolyticGenotypeHepacivirusInterferon alpha-2Esophageal and Gastric VaricesAntiviral AgentsPolymorphism Single NucleotidePolyethylene GlycolsSettore BIO/13 - Biologia ApplicataRibavirinHumanschronic hepatitis C cirrhosis IL-28B inosine triphosphatase sustained virologic responseProspective StudiesPyrophosphatasesGenetic Association StudiesAgedSettore MED/12 - GastroenterologiaDose-Response Relationship DrugInterleukinsInterferon-alphaSequence Analysis DNAHepatitis C ChronicMiddle AgedRecombinant ProteinsLogistic ModelsTreatment OutcomeMultivariate AnalysisDrug Therapy CombinationFemaleInterferonsJournal of viral hepatitis
researchProduct

Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.

2020

Metabolic associated fatty liver disease (MAFLD) is the most prevalent liver disease in Western nations, with high heritability. A recent study of Japanese patients with the disease suggested that TLL1 rs17047200 is associated with fibrosis; whether a similar association is observed in Caucasian patients with MAFLD is unknown. We investigated the association of the TLL1 rs17047200 polymorphism with liver fibrosis in a cohort of Caucasian patients with MAFLD (n = 728). We also investigated whether TLL1 expression is altered during liver injury in humans, in murine models of fibrosis, and in in-vitro. While TLL1 expression is upregulated in the liver of humans with MAFLD and in mice, the rs17…

Liver CirrhosisMaleSteatosisGene ExpressionDiseasePathology and Laboratory MedicineInbred C57BLGastroenterologyPathogenesisCytopathologyCohort StudiesLiver diseaseMice0302 clinical medicineFibrosisMedicine and Health SciencesLiver injury0303 health sciencesMultidisciplinaryLiver DiseasesQFatty liverRTLL1Single NucleotideMiddle Aged3. Good healthUp-RegulationAdult; Animals; Cohort Studies; Fatty Liver; Female; Genetic Variation; Humans; Liver Cirrhosis; Male; Mice; Mice Inbred C57BL; Middle Aged; Tolloid-Like Metalloproteinases; Up-Regulation; Polymorphism Single NucleotideMedicineLiver Fibrosis030211 gastroenterology & hepatologyFemaleAnatomyResearch ArticleAdultmedicine.medical_specialtyHistologyTolloid-Like MetalloproteinasesSettore MED/12 - GASTROENTEROLOGIAScienceGastroenterology and HepatologyPolymorphism Single Nucleotide03 medical and health sciencesInternal medicinemedicineGeneticsAnimalsHumansPolymorphism030304 developmental biologyNutritionbusiness.industryAdult Animals Cohort Studies Fatty Liver Female Genetic Variation Humans Liver Cirrhosis Male Mice Mice Inbred C57BL Middle Aged Tolloid-Like Metalloproteinases Up-Regulation Polymorphism Single NucleotideBiology and Life SciencesGenetic Variationmedicine.diseaseFibrosisDietFatty LiverMice Inbred C57BLn/aAnatomical PathologySteatosisbusinessDevelopmental Biology
researchProduct

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection

2012

Background: Limited data are available on hepatic steatosis (HS) in HIV patients who are not infected with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced liver fibrosis and/or cardiovascular disease risk. Methods: Fifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral therapy (HAART) were recorded. Cardiovasc…

Liver CirrhosisMaleSteatosisSettore MED/09 - Medicina InternaLipodystrophyAntiretroviral medicationHIV Infectionsmedicine.disease_causeGastroenterologyHIV/HCV co-infectedLiver diseaseRisk FactorsAntiretroviral Therapy Highly ActivePrevalenceMedicineProspective StudiesSteatosis HIV HIV/HCV co-infected Non-alcoholic fatty liver disease Liver disease Antiretroviral medication Metabolic syndrome LipodystrophyUltrasonographyeducation.field_of_studySettore MED/12 - GastroenterologiaFramingham Risk ScoreCoinfectionvirus diseasesGeneral MedicineMiddle AgedMetabolic syndromeHepatitis CInfectious DiseasesCardiovascular DiseasesFemaleLipodystrophyLiver diseaseViral loadMicrobiology (medical)Adultmedicine.medical_specialtySettore MED/17 - Malattie InfettiveAnti-HIV AgentsHepatitis C virusPopulationInternal medicineHumanseducationbusiness.industryHIVmedicine.diseaseFatty LiverImmunologyMultivariate AnalysisLiver functionbusinessTransient elastographyNon-alcoholic fatty liver disease
researchProduct

Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection

2009

Background Genotype 1 (G1) hepatitis C virus (HCV) is associated with insulin resistance (IR) and its clearance seems to improve insulin sensitivity. We aimed to evaluate the time course of IR in response to antiviral therapy in non-diabetic, non-cirrhotic G1 HCV patients and to assess the effect of metabolic factors on sustained virological response (SVR). Methods A total of 83 consecutive treatment-naive G1 chronic hepatitis C (CHC) patients were evaluated by anthropometric and metabolic measurements, including IR using the homeostasis model assessment (HOMA). Patients were considered to have IR if HOMA was >2.7. All cases had a liver biopsy scored for staging, grading and steatosis. A…

Liver CirrhosisMaleTime FactorsCirrhosisGenotypemedicine.medical_treatmentHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsBody Mass IndexSex FactorsInsulin resistanceDiabetes mellitusGenotypemedicineHumansPharmacology (medical)PharmacologySettore MED/12 - Gastroenterologiabusiness.industryInsulinHepatitis C ChronicMiddle Agedmedicine.diseaseANTIVIRAL THERAPYFatty LiverLogistic ModelsTreatment OutcomeInfectious DiseasesTime courseImmunologyHCVFemaleViral diseaseWaist CircumferencebusinessINSULIN RESISTANCE
researchProduct